Home  »  Industry   »  The clock is ticking: Sunshine Biopharma Inc. (SBF...

The clock is ticking: Sunshine Biopharma Inc. (SBFM)

At the end of the latest market close, Sunshine Biopharma Inc. (SBFM) was valued at $1.14. In that particular session, Stock kicked-off at the price of $1.16 while reaching the peak value of $1.17 and lowest value recorded on the day was $1.1199. The stock current value is $1.26.Recently in News on August 4, 2022, Sunshine Biopharma Files Its Second Quarter Report With the SEC. Company Reports Significant Increase in Cash on Hand as a Result of Recent Financings. You can read further details here

Sunshine Biopharma Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $15.5000 on 01/03/22, with the lowest value was $1.0300 for the same time period, recorded on 07/29/22.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Sunshine Biopharma Inc. (SBFM) full year performance was -95.06%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Sunshine Biopharma Inc. shares are logging -95.76% during the 52-week period from high price, and 22.82% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.03 and $29.80.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 850445 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Sunshine Biopharma Inc. (SBFM) recorded performance in the market was -90.25%, having the revenues showcasing -56.98% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 21.74M, as it employees total of 3 workers.

Market experts do have their say about Sunshine Biopharma Inc. (SBFM)

During the last month, 0 analysts gave the Sunshine Biopharma Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.1678, with a change in the price was noted -1.66. In a similar fashion, Sunshine Biopharma Inc. posted a movement of -57.44% for the period of last 100 days, recording 7,205,242 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for SBFM is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical breakdown of Sunshine Biopharma Inc. (SBFM)

Raw Stochastic average of Sunshine Biopharma Inc. in the period of last 50 days is set at 24.39%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 24.39%. In the last 20 days, the company’s Stochastic %K was 16.26% and its Stochastic %D was recorded 12.33%.

Bearing in mind the latest performance of Sunshine Biopharma Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -90.25%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -88.62%, alongside a downfall of -95.06% for the period of the last 12 months. The shares -0.87% in the 7-day charts and went up by -0.87% in the period of the last 30 days. Common stock shares were lifted by -56.98% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts